Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and rai

Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises th

10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science

10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science

Morgan Stanley analyst Tejas Savant maintains 10x Genomics (NASDAQ:TXG) with a Equal-Weight and r

JP Morgan analyst Casey Woodring maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises th

10x Genomics (NASDAQ:TXG) affirms FY2026 sales outlook from $600.000 million-$625.000 million to $60

10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.10) per share which beat the analyst cons

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises t

B of A Securities analyst Derik De Bruin maintains 10x Genomics (NASDAQ:TXG) with a Neutral and r

Citigroup analyst Patrick Donnelly maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises

William Blair upgrades 10x Genomics, citing AI-driven data demand, improving execution and Xenium va

Bioptimus, a global AI company building the world's first world model for biology, today announc

Stifel analyst Daniel Arias maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises the price t

UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price t

Stifel analyst Daniel Arias maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises the price t

TD Cowen analyst Dan Brennan maintains 10x Genomics (NASDAQ:TXG) with a Hold and raises the price

10x Genomics (NASDAQ:TXG) sees FY2026 sales of $600.000 million-$625.000 million vs $611.577 million

10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.13) per share which beat the analyst cons

Gold fell 9.5% and silver collapsed 27%, sparking a mining stock bloodbath as markets repriced Fed r

Ark Invest, led by Cathie Wood, issued another "Big Ideas" list on Wednesday, sharing themes

Cathie Wood's Ark Invest unveiled its "big ideas" for 2025 in a cryptic list, challengin

Collaboration with Dana-Farber Cancer Institute aims to identify biomarkers linked to treatment resp

Multi-phase initiative will generate single cell and spatial data from over 20,000 samples across le

Study aims to identify single cell immune signatures of disease activity and treatment response to s

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a col

TD Cowen analyst Dan Brennan maintains 10x Genomics (NASDAQ:TXG) with a Hold and raises the price

CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises t

Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises th

Citigroup analyst Patrick Donnelly downgrades 10x Genomics (NASDAQ:TXG) from Buy to Neutral and a

Morgan Stanley analyst Tejas Savant downgrades 10x Genomics (NASDAQ:TXG) from Overweight to Equal

Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and rai

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises t

JP Morgan analyst Casey Woodring maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises th

UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price t

Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises th